PTC Therapeutics, Inc.

NasdaqGS:PTCT 주식 보고서

시가총액: US$2.6b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PTC Therapeutics 미래 성장

Future 기준 확인 0/6

PTC Therapeutics은 연간 수입과 매출이 각각 60%와 7.5% 증가할 것으로 예상되고 EPS는 연간 60.3%만큼 증가할 것으로 예상됩니다.

주요 정보

59.7%

수익 성장률

60.0%

EPS 성장률

Biotechs 수익 성장24.5%
매출 성장률7.3%
향후 자기자본 수익률n/a
애널리스트 커버리지

Good

마지막 업데이트21 Jun 2024

최근 미래 성장 업데이트

Recent updates

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

May 22

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

May 22
Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03
PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23
An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18
Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02
An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

May 27
Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

PTC Therapeutics: One Of The Leaders In The Treatment Of Rare Diseases

Apr 11

수익 및 매출 성장 예측

NasdaqGS:PTCT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026943-572503259
12/31/2025843-203884611
12/31/2024752-382-55-19312
3/31/2024928-579-199-58N/A
12/31/2023938-627-279-158N/A
9/30/2023798-642-343-224N/A
6/30/2023819-618-364-248N/A
3/31/2023770-571-403-289N/A
12/31/2022699-559-509-357N/A
9/30/2022697-531-409-260N/A
6/30/2022618-556-422-273N/A
3/31/2022569-522-395-249N/A
12/31/2021539-524-337-251N/A
9/30/2021492-455-327-247N/A
6/30/2021472-391-250-169N/A
3/31/2021430-454-271-213N/A
12/31/2020381-438-250-194N/A
9/30/2020358-441-193-140N/A
6/30/2020311-432-221-182N/A
3/31/2020322-292-198-138N/A
12/31/2019307-252-144-99N/A
9/30/2019297-222-142-104N/A
6/30/2019279-213-116-85N/A
3/31/2019262-181-72-54N/A
12/31/2018265-128-43-28N/A
9/30/2018256-7809N/A
6/30/2018245-61-91-10N/A
3/31/2018224-69-783N/A
12/31/2017194-79N/A-10N/A
9/30/2017142-107N/A-45N/A
6/30/2017123-108N/A-53N/A
3/31/201790-130N/A-91N/A
12/31/201683-142N/A-104N/A
9/30/201670-166N/A-121N/A
6/30/201657-174N/A-124N/A
3/31/201648-174N/A-129N/A
12/31/201537-170N/A-124N/A
9/30/201537-147N/A-102N/A
6/30/201529-131N/A-91N/A
3/31/201524-118N/A-80N/A
12/31/201425-94N/A-57N/A
9/30/201417-84N/A-64N/A
6/30/201432-62N/A-52N/A
3/31/201437-51N/A-53N/A
12/31/201335-66N/A-47N/A
9/30/201337-48N/A-43N/A
6/30/201328-51N/A-45N/A

애널리스트 미래 성장 예측

수입 대 저축률: PTCT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: PTCT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: PTCT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: PTCT 의 수익(연간 7.5% ) US 시장( 8.7% 보다 느리게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: PTCT 의 수익(연간 7.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: PTCT 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견